TAVIST-1

LOE Approaching

clemastine fumarate

Novartis
NDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT05359653Phase 1/2Recruiting

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Started Aug 2023
74 enrolled
Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
Company
Novartis
Novartis
BASEL, Switzerland
663 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.